Recently, the seminar on “China-US Practical Solutions to Pharmaceutical Patent Disputes” was successfully held at Hangzhou Medical Port. The event was co-organized by Linda Liu & Partners, Beijing Wei Chixue Law Firm, and a renowned US law firm.
 

Focusing on core IP issues in the biopharmaceutical sector, the seminar brought together legal and IP experts from China and the US to share in-depth insights on pharmaceutical patent strategies, dispute resolution, and cross-border practices, offering actionable solutions for innovative pharmaceutical companies. The event was supported by the Zhejiang Free Trade Development Center and the Hangzhou Medical Port Management Office.
 
Two US attorneys delivered a keynote titled “Pharmaceutical Patent Disputes in the US Market: Key Issues for R&D and In-House Teams,” analyzing critical risks, compliance points, and response strategies for companies entering the US market from both R&D and patent perspectives.
 

 
Ms. Chen Jie, the President of Beijing Wei Chixue Law Firm, presented “Offense and Defense in Technical IP Disputes.” Using real-world cases, she systematically explained strategies for rights enforcement, defense arguments, and practical tactics in technical IP disputes, providing clear guidance for corporate IP dispute management.
 
The seminar addressed the innovation needs of the biopharmaceutical industry, building a platform for China-US IP exchange. It effectively helped pharmaceutical companies in Hangzhou and the Yangtze River Delta enhance their capabilities in patent risk prevention, cross-border dispute resolution, and international operations, injecting professional impetus into high-quality innovation in the biopharmaceutical sector.